On Dec. 11, 2020, the combination of baricitinib, an anti-inflammatory drug, and remdesivir, an antiviral, reduced time to recovery for people hospitalized with COVID-19, according to clinical trial results published in the New England Journal of Medicine.

The study was supported by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.